Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Qiagen and Eli Lilly to Develop First QIAstat-Dx IVD Panel for Neurodegenerative Applications

By LabMedica International staff writers
Posted on 06 Sep 2024

QIAGEN N. More...

V. (Venlo, the Netherlands) has entered into a collaboration with Eli Lilly and Company (Indianapolis, IN, USA) to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes. The QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping and will detect all APOE genotypes (APOE2, APOE3, APOE4) which can play a role in the diagnosis of Alzheimer’s disease. People carrying the APOE4 genotype have a greater risk of developing Alzheimer's which is the most common cause of dementia and are likely to do so earlier in life in comparison to others. Individuals carrying two copies of this genotype (homozygous) are most likely to develop clinical symptoms of the disease.

The panel will be integrated with QIAGEN's multiplex testing platform QIAstat-Dx, marking the first publicly disclosed collaboration for the system’s clinical application in neurodegenerative diseases. The QIAstat‑Dx system, designed for laboratory use, utilizes cost-efficient, single-use cartridges with built‑in sample processing and on-board reagents. Employing multiplex real-time PCR, it reliably detects genetic variants, with results in approximately one hour. With over 4,000 instruments placed worldwide, QIAstat‑Dx enjoys a strong footprint in infectious disease testing, which has now expanded into other disease and application areas.

“Our collaboration with Lilly to develop the QIAstat-Dx IVD panel underlines our commitment to advancing healthcare with a unique breadth of testing technologies and platforms, now also including multiplexing capabilities on QIAstat‑Dx,” said Jonathan Arnold, Vice President and Head of Translational Science and Precision Diagnostics at QIAGEN. “By providing precise APOE genotyping, we aim to better inform treatment considerations for Alzheimer’s patients, providing valuable insight in their diagnostic journey.”

“When offering a diagnostic test for clinical use, it is imperative that it be high-quality, accurate and accessible to patients,” added Anthony Sireci, M.D., MSc., Head of Diagnostics Development & Commercialization for Eli Lilly and Company. “We are working with QIAGEN to generate data for this APOE test because of their expertise in developing diagnostic assays and their global reach.”

Related Links:
QIAGEN N.V.
Eli Lilly and Company


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Portable Electronic Pipette
Mini 96
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Dormant tumor cells evade imaging tests and may later reactivate to spread metastatic breast cancer (Photo courtesy of David A. Litman/Shutterstock)

MRD Testing Can Identify Breast Cancer Survivors at Higher Risk of Recurrence

Breast cancer survival rates continue to improve, but recurrence remains incurable and affects around 30% of patients. Some subtypes, like triple negative and HER2+, relapse within years, while ER+ cancers... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.